Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial

Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial

Abstract Background Inflammation and neurohormonal activation play a significant role in the adverse outcome seen in acute myocardial infarction (AMI) and the development of cardiogenic shock (CS), which is associated with a mortality rate up to 50%. Treatment with anti-inflammatory drugs such as to...

Full description

Saved in:
Bibliographic Details
Main Authors: Joakim Bo Kunkel, Sarah Louise Duus Holle, Christian Hassager, Redi Pecini, Sebastian Wiberg, Pernille Palm, Lene Holmvang, Lia Evi Bang, Jesper Kjærgaard, Jakob Hartvig Thomsen, Thomas Engstrøm, Jacob Eifer Møller, Jacob Thomsen Lønborg, Martin Frydland, Helle Søholm
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Trials
Subjects:
Acute myocardial infarction
Cardiogenic shock
Neurohormonal activation
ProBNP
Inflammation
Tocilizumab
Online Access:https://doi.org/10.1186/s13063-024-08573-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13063-024-08573-0

Similar Items